Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials

We read the Maastricht VI/Florence consensus report published in GUT with great interest.1 The report suggested that vonoprazan-based therapy is superior, or not inferior, to conventional proton pump inhibitor (PPI)-based triple therapies for Helicobacter pylori eradication.1 However, the number of randomised controlled trials (RCTs) was small and the majority of previous trials were conducted in Japan.2–5 Recently, several new RCTs from other populations have been reported.6–8 Therefore, we conducted an updated systematic review and meta-analysis of RCTs to compare the efficacy and tolerability of vonoprazan and PPI-based therapies for H. pylori eradication. Detailed methods of the inclusion and exclusion criteria, systematic review, and statistical methods were shown in , and the registration number is CRD42023394825. Of the 489 articles identified, 476 articles were excluded (). A total of 13 RCTs were...

Source: Gut - April 5, 2024 Category: Gastroenterology Authors: Chen, P.-Y., Tsai, F.-P., Chen, M.-J., Yang, H.-Y., Wu, M.-S., Liou, J.-M. Tags: Gut PostScript Source Type: research